SNX16 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:64089, HGNC:14980, MIM:614903, NM_001348189, NM_022133, NM_152836, NM_152837, NP_001335118, NP_071416, NP_690049, NP_690050, NR_145472, NR_145473, NR_145474, NR_145475, SNX16, XM_005251282, XM_011517574, XP_005251339, XP_011515876, XR_002956641, sorting nexin 16

Id:ENSG00000104497

Entrez:64089

Ensembl:ENSG00000104497

Description:sorting nexin 16

This gene encodes a member of the sorting nexin family. Members of this family contain a phox (PX) domain, which is a phosphoinositide binding domain, and are involved in intracellular trafficking. The protein encoded by this gene associates with late endosome membranes as is involved in tubule formation, cholesterol transport, and transport of tetraspanin CD81. The encoded protein also inhibits cell migration and tumorigenesis. [provided by RefSeq, Jan 2017]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SNX16's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SNX16.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SNX16.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SNX16.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SNX16.

Results found

Linked to

	Label	Description
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE187006 3 V 2 VALPROIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE230634 PARP inhibition 0 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173201 0 V 1 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 7 V 1 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 8 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE198982,GSE198986 1 V 2 DAUNORUBICIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE74490 0 V 1 TRIPTOLIDE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193258,GSE193259 5 V 4 OSIMERTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE187006 3 V 2 VALPROIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE230634 PARP inhibition 0 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE173201 0 V 1 CISPLATIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 7 V 1 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 8 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE198982,GSE198986 1 V 2 DAUNORUBICIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE74490 0 V 1 TRIPTOLIDE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE193258,GSE193259 5 V 4 OSIMERTINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 cisplatin 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.